Where I see patients (1)
My reviews
Selected research
-
Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy.
Blood
-
Structure-guided engineering of CCL27 enhances natural ligand CAR T-cells against CCR10 for multiple myeloma.
bioRxiv : the preprint server for biology
-
Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR T cells.
Blood
4.9